Department of Biomedical Science, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.
Evid Based Complement Alternat Med. 2013;2013:157456. doi: 10.1155/2013/157456. Epub 2013 Aug 7.
Background. Researchers focused on developing traditional therapies as pharmacological medicines to treat liver cirrhosis. Objectives. Evaluating the hepatoprotective activity of Boesenbergia rotunda (BR) rhizome ethanolic extract on thioacetamide-induced liver cirrhosis in rats. Methods. Male Sprague-Dawley rats were intraperitoneally injected with 200 mg/kg TAA 3 times/week and daily oral administration of 250 mg/kg, 500 mg/kg of BR extract, and 50 mg/kg of the reference drug Silymarin for 8 weeks. At the end of the experiment, Masson's trichrome staining was used to measure the degree of liver fibrosis. Hepatic antioxidant enzymes (CAT and GPx), nitrotyrosine, cytochrome (P450 2E1), matrix metalloproteinase (MMP-2 and MMP-9), tissue inhibitor of metalloproteinase (TIMP-1), and urinary 8-hydroxyguanosine were measured. Serum levels of transforming growth factor TGF- β 1, nuclear transcription factor NF- κ B, proinflammatory cytokine IL-6, and caspase-3 were evaluated. Serum protein expression and immunohistochemistry of proapoptotic Bax and antiapoptotic Bcl-2 proteins were measured and confirmed by immunohistochemistry of Bax, Bcl-2, and proliferating cell nuclear antigen (PCNA). Results. BR treatment improved liver histopathology, immunohistochemistry, and biochemistry, triggered apoptosis, and inhibited cytokines, extracellular matrix proteins, and hepatocytes proliferation. Conclusion. Liver cirrhosis progression can be inhibited by the antioxidant and anti-inflammatory activities of BR ethanolic extract while preserving the normal liver status.
研究人员专注于开发传统疗法作为药物治疗肝硬化。目的：评估布渣叶（BR）根茎乙醇提取物对硫代乙酰胺诱导的大鼠肝硬化的肝保护活性。方法：雄性 Sprague-Dawley 大鼠每周腹腔注射 200mg/kg TAA 3 次，同时每天口服 250mg/kg、500mg/kg BR 提取物和 50mg/kg 对照药物水飞蓟素，共 8 周。实验结束时，使用 Masson 三色染色测量肝纤维化程度。测定肝抗氧化酶（CAT 和 GPx）、硝基酪氨酸、细胞色素（P450 2E1）、基质金属蛋白酶（MMP-2 和 MMP-9）、金属蛋白酶组织抑制剂（TIMP-1）和尿 8-羟基鸟苷。评估血清转化生长因子 TGF-β1、核转录因子 NF-κB、促炎细胞因子 IL-6 和半胱氨酸天冬氨酸蛋白酶-3 的水平。通过 Bax 和 Bcl-2 蛋白的免疫组化证实了血清蛋白表达和促凋亡 Bax 和抗凋亡 Bcl-2 蛋白的免疫组化。结果：BR 治疗改善了肝组织病理学、免疫组织化学和生物化学，触发了细胞凋亡，并抑制了细胞因子、细胞外基质蛋白和肝细胞增殖。结论：BR 乙醇提取物的抗氧化和抗炎活性可抑制肝硬化的进展，同时保持正常的肝状态。
